Postexposure treatment of marburg virus infection

Emerging Infectious Diseases

Volumn 16, Issue 7, 2010, Pages 1119-1122

  Geisbert, Thomas W ^a   Hensley, Lisa E ^b   Geisbert, Joan B ^a   Leung, Anders ^c   Johnson, Joshua C ^b   Grolla, Allen ^c   Feldmann, Heinz ^d  

^a National Emerging Infectious Diseases Laboratories Institute   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MARBURG VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VACCINE; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; IMMUNE RESPONSE; MARBURG HEMORRHAGIC FEVER; MARBURG VIRUS; NONHUMAN; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY; SINGLE DRUG DOSE; SYMPTOM; VESICULAR STOMATITIS VIRUS; VIREMIA; VIRUS INFECTIVITY; VIRUS RECOMBINANT; VIRUS STRAIN; ANIMAL; GENETICS; IMMUNOLOGY; MARBURG VIRUS DISEASE; MONKEY DISEASES; VESICULAR STOMATITIS INDIANA VIRUS;

ANIMALS; MACACA MULATTA; MARBURG VIRUS DISEASE; MARBURGVIRUS; MONKEY DISEASES; VACCINES, SYNTHETIC; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL VACCINES;

EID: 77954451839     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1607.100159     Document Type: Article

References (14)

1. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, Griffi n DE, Lamb RA, Martin MA, Roizman B, et al., editors. Fields virology, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 1409-48.
2. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet. 2003;362:1953-8, DOI: 10.1016/S0140-6736(03)15012-X
3. Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, Larsen T, et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis. 2007;196(Suppl 2):S390-9, DOI: 10.1086/520598
4. Geisbert TW, Hensley LE, Kagan E, Zhaoying Yu E, Geisbert JB, Daddario-DiCaprio K, et al. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis. 2006;193:1650-7, DOI: 10.1086/504267
5. Enterlein S, Warfield KL, Swenson DL, Stein DA, Smith JL, Gamble CS, et al. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother. 2006;50:984-93, DOI: 10.1128/AAC.50.3.984-993.2006
6. Warfi eld KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, Blouch R, et al. Gene-specifi c countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2006;2:e1. DOI: 10.1371/journal.ppat.0020001
7. Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, Fritz EA, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an effi cacy assessment. Lancet. 2006;367:1399-404. DOI: 10.1016/S0140-6736(06)68546-2
8. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, Wagner R, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of fi loviruses and arenaviruses. J Virol. 2004;78:5458-65. DOI: 10.1128/JVI.78.10.5458-5465.2004
9. Feldmann H, Jones SM, Daddario-Dicaprio KM, Geisbert JB, Stroher U, Grolla A, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 2007;3:e2. DOI: 10.1371/journal.ppat.0030002
10. Geisbert TW, Daddario-Dicaprio KM, Williams K, Geisbert JB, Leung A, Feldmann F, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol. 2008;82:5664-8. DOI: 10.1128/JVI.00456-08
11. International Society for Infectious Diseases. Ebola, lab accident death-Russia (Siberia) [cited 2004 May 22]. http://www.promed mail.org.
12. Kortepeter MG, Martin JW, Rusnak JM, Cieslak TJ, Warfi eld KL, Anderson EL, et al. Managing potential laboratory exposure to Ebola virus by using a patient biocontainment care unit. Emerg Infect Dis. 2008;14:881-7. DOI: 10.3201/eid1406.071489
13. Tuffs A. Experimental vaccine may have saved Hamburg scientist from Ebola fever. BMJ. 2009;338:b1223. DOI: 10.1136/bmj.b1223
14. Gonchar NI, Pshenichnov VA, Pokhodiaev VA, Lopatov KL, Firsova IV. The sensitivity of different experimental animals to Marburg virus. Vopr Virusol. 1991;36:435-7.